Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, October 9, 2017
[ Mon, Oct 09th 2017
] - WOPRAI
[ Mon, Oct 09th 2017
] - WOPRAI
[ Mon, Oct 09th 2017
] - WOPRAI
[ Mon, Oct 09th 2017
] - WOPRAI
[ Mon, Oct 09th 2017
] - WOPRAI
[ Mon, Oct 09th 2017
] - WOPRAI
[ Mon, Oct 09th 2017
] - WOPRAI
[ Mon, Oct 09th 2017
] - WOPRAI
[ Mon, Oct 09th 2017
] - WOPRAI
[ Mon, Oct 09th 2017
] - WOPRAI
[ Mon, Oct 09th 2017
] - WOPRAI
[ Mon, Oct 09th 2017
] - WOPRAI
[ Mon, Oct 09th 2017
] - WOPRAI
Fri, October 6, 2017
[ Fri, Oct 06th 2017
] - WOPRAI
[ Fri, Oct 06th 2017
] - WOPRAI
[ Fri, Oct 06th 2017
] - WOPRAI
[ Fri, Oct 06th 2017
] - WOPRAI
[ Fri, Oct 06th 2017
] - WOPRAI
[ Fri, Oct 06th 2017
] - WOPRAI
[ Fri, Oct 06th 2017
] - WOPRAI
[ Fri, Oct 06th 2017
] - WOPRAI
[ Fri, Oct 06th 2017
] - WOPRAI
[ Fri, Oct 06th 2017
] - WOPRAI
[ Fri, Oct 06th 2017
] - WOPRAI
Matthew Harrison Maintained (BMRN) at Buy with Increased Target to $117 on, Oct 6th, 2017
Matthew Harrison of Morgan Stanley, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $115 to $117 on, Oct 6th, 2017.
Matthew has made no other calls on BMRN in the last 4 months.
There are 4 other peers that have a rating on BMRN. Out of the 4 peers that are also analyzing BMRN, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Kennen MacKay of "RBC Capital" Initiated at Hold and Held Target at $93 on, Friday, September 15th, 2017
- Vincent Chen of "Bernstein" Initiated at Hold and Held Target at $89 on, Thursday, July 27th, 2017
These are the ratings of the 2 analyists that currently disagree with Matthew
- Christopher Raymond of "Piper Sandler" Initiated at Buy on, Thursday, September 14th, 2017
- Josh Schimmer of "Evercore ISI Group" Initiated at Buy on, Thursday, August 17th, 2017
